Syndesis Health
11.5.2023 15:08:38 CEST | ACCESS Newswire | Press release
NEW YORK, NY / ACCESSWIRE / May 11, 2023 / Syndesis Health announced today that it has signed a research collaboration and information sharing agreement with Fundación Cardio Infantil Instituto de Cardiología (LaCardio), a leading cardiovascular hospital in Bogotá, Colombia.
LaCardio is joining the Syndesis Health Network alongside progressive healthcare institutions from South America, Asia, and Africa. Syndesis Health created its global network of healthcare partners to enable secure access to a multi-country, real-world data set. Syndesis Health's global research platform, Syntium, unifies de-identified clinical data from these healthcare partners in a secure, ethical, and compliant manner for the improvement of global health outcomes.
The partnership enables LaCardio to extend its commitment to improving patient outcomes by leveraging the Syndesis Health platform for access to data, analytics, and other technical resources. In addition, the partnership enables the hospital to engage in collaborative research opportunities with peer institutions around the world that are a part of the network.
Hans Godfrey, COO and head of Latin America data partnerships for Syndesis Health, commented: "We believe that the future of healthcare will be data-driven. With LaCardio as a partner in the Syndesis Health Network, we will together expand the potential for real-world data to enable research and treatments in the cardiovascular space."
Dr. Juan Gabriel Cendales, Executive Director of LaCardio, stated: "One of the strategic priorities of LaCardio as a university hospital and scientific research center is to continue advancing in scientific studies while contributing to the health of the people in Colombia and the region. Having valuable data, evaluating, and applying tools, such as AI, in healthcare allows us to anticipate the needs of the population, evaluate new alternatives and improve the experience of patients and collaborators. This alliance is part of the path in which we are working to be the hospital of the future."
About Syndesis Health
Syndesis Health accelerates research and innovation for healthcare and life sciences companies. The company was founded on the potential for real-world clinical data to advance medical research, improve patient health outcomes, and inform healthcare policy decisions. The Syndesis Health Network enables secure collaboration amongst member organizations and is powered by Syntium, the Syndesis data platform. Visit our website at https://syndesis.com to learn more.
About LaCardio
Fundación Cardioinfantil-LaCardio is a private, nonprofit institution with 50 years of experience. Founded in 1973 by brothers Reinaldo and Camilo Cabrera Polanía, it is one of the few Colombian institutions accredited by the Joint Commission International and has national accreditation granted by ICONTEC. Since 2015, LaCardio is recognized as a University Hospital by the Intersectoral Committee for Human Talent in Health, in compliance of the Ministries of Health and Education of Colombia. Its commitment to health transcends through its mission: to operate on low-income children with heart problems. The MERCO 2022 ranking positioned LaCardio as the best hospital in Colombia. In 2021, Americaeconomia ranked LaCardio 5th in Latin America, evaluating key processes and indicators, including patient safety & dignity, human capital, capacity, and knowledge management.
Contact Information
Leah Patterson
Chief Marketing Officer
leah.patterson@syndesis.com
+1.646.274.1420
Liliana Milena Toro Sánchez Sánchez
Marketing & Communications
lmtoro@lacardio.org
+3157288712
SOURCE: Syndesis Health
To view this piece of content from stats.newswire.com, please give your consent at the top of this page.View source version on accesswire.com:
https://www.accesswire.com/754175/Syndesis-Health-LaCardio-Sign-Research-Collaboration-Agreement
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
Datavault AI Chief Executive Officer and President Issues Letter to Stockholders Highlighting 2025 Accomplishments and Outlook for 20265.2.2026 12:00:00 CET | Press release
Datavault AI signed $49M of Tokenization and Technology Licensing agreements in Q4'25 that impact FY2025 and FY2026 Revenue. Revenue: Datavault AI expects at least $30 million in revenue for FY2025, compared to $2.7 million in FY2024. This represents an increase of more than 1,000% growth in our revenue over 2024. The Company continues to expand to drive substantial near- and long-term accretion to our cash flows and earnings with a revenue target for 2026 of at least $200 million. PHILADELPHIA, PENNSYLVANIA / ACCESS Newswire / February 5, 2026 / Datavault AI Inc. (NASDAQ:DVLT) ("Datavault AI" or the "Company"), a leader in data monetization, credentialing, digital engagement and real-world asset (RWA) tokenization technologies, today issued a letter from Nathaniel Bradley, its Chief Executive Officer, to its stockholders highlighting the Company's accomplishments in 2025 and its outlook for 2026. A MESSAGE FROM OUR CHIEF EXECUTIVE OFFICER Dear Datavault AI Stockholders, I would like t
AGFA HealthCare Named Best in KLAS(R) 2026 Across Three Enterprise Imaging Segments in the United States4.2.2026 15:45:00 CET | Press release
Industry recognition for the third consecutive year reinforces AGFA HealthCare's clinician-first commitment, and leadership in empowering connected, high-performance imaging environments MORTSEL, BE / ACCESS Newswire / February 4, 2026 / AGFA HealthCare today announced that it has been named Best in KLAS® 2026 across three Enterprise Imaging segments in the United States, with two awards earned for the second consecutive year, underscoring the company's continued leadership in delivering clinician-first imaging solutions trusted by healthcare organizations worldwide. The recognition comes as KLAS Research marks its 30th anniversary, celebrating three decades of amplifying the voice of healthcare providers through independent, data-driven insights. AGFA HealthCare's Best in KLAS distinctions reflect strong customer validation of its Enterprise Imaging platform - designed to empower clinicians to stay in their flow, reduce complexity across imaging workflows, and enable confident clinica
Preservica Redefines Digital Preservation with Powerful Built-In AI Tools4.2.2026 15:00:00 CET | Press release
OXFORD, UK and BOSTON, MA / ACCESS Newswire / February 4, 2026 / Preservica, the leader in AI-powered Active Digital Preservation™, today announced the rollout of integrated, human-centered AI tools and flexible AI Credits across its product editions. These new features make AI assistance a seamless part of everyday archival workflows, empowering organizations of all sizes to safely adopt AI and scale its use as their needs grow. "With the sheer volume of digital content in backlogs and being created daily, using AI to assist in archival tasks has now become essential" says Stuart Reed, Chief Product Officer at Preservica "Seamlessly integrating human-centered AI tools across our product editions turns AI for Digital Preservation into reality - enabling organizations of all sizes to accelerate routine work, cut backlogs and enhance discovery." Developed in collaboration with Preservica's user community and refined through the company's highly rated AI Workshop series, these embedded to
Karbon-X Files Quarterly Report on Form 10-Q Highlighting Strong Revenue Growth and Commercial Scale4.2.2026 15:00:00 CET | Press release
CALGARY, AB / ACCESS Newswire / February 4, 2026 / Karbon-X Corp. (OTCQX:KARX) ("Karbon-X" or the "Company"), a vertically integrated climate solutions company, today announced that it has filed its Quarterly Report on Form 10-Q for the six months ended November 30, 2025. The filing highlights continued momentum in Karbon-X's commercial operations, driven by significant revenue growth and the expansion of its global carbon activities across both compliance and voluntary markets. "Over the past several quarters, we transformed Karbon-X from a developing platform into a scaled, revenue-generating global operator," said Chad Clovis, Chief Executive Officer of Karbon-X Corp. "Revenue increased to $56.5 million (USD), compared to $1.3 million (USD) in the prior-year period, reflecting the strength of our commercial strategy and the growing demand for high-integrity carbon solutions. As we continue to invest in scaling our operations, our expanding global footprint, improved profitability, a
Axon Neuroscience's Immunotherapy Selected for a Landmark Combination-Therapy Alzheimer’s Clinical Trial in US, Supported by a USD 151 Million Grant4.2.2026 14:00:00 CET | Press release
Axon Neuroscience's active tau immunotherapy AADvac1 has been selected as the first tau-targeted therapy to enter a groundbreaking U.S. Alzheimer's disease phase 2 clinical trial (supported by a USD 151 million grant) and, simultaneously, a new platform trial for progressive supranuclear palsy (PSP) (supported by a USD 75 million grant) SAN FRANCISCO, CA / ACCESS Newswire / February 4, 2026 / Axon Neuroscience, a global leader in immunotherapy for human neurodegenerative diseases with an internationally recognized scientific team, announces the achievement of two historic milestones with the potential to significantly influence the future treatment of Alzheimer's disease and progressive supranuclear palsy (PSP): 1. AADvac1 Selected as the First Tau Therapy in the Phase 2 Alzheimer's Tau Platform (ATP) Combination-Therapy Trial An independent panel of leading U.S. scientific and clinical experts selected AADvac1 as the first therapy targeting pathological tau protein to be evaluated in
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom